Confirm delete?

Bertin Bioreagent
All categories
Contact Us
You are here :

MDA 19

  • Zoom
    MDA 19
  • MDA 19
Cat No: 10563
Biochemicals - Drugs Of Abuse

MDA 19 is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63.4 nM) that is 14-fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM).{18383} Surprisingly, it acts as an...


This article is not for sale online.
Contact us for more information about this article.

Territorial Availability: Available through Bertin Technologies only in France
Technical Warning: Bertin Technologies restricts the sale of this product to licensed controlled substance laboratories and qualified academic research institutions. Please contact us for further details.
Special Advice: Please check regulation status before ordering; additionel fees can apply.
  • (2Z)-2-(1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide, benzoic acid
Correlated keywords:
  • agonists cannabinoids CB2 CB1 pains 1104302-26-2 tactile allodynia paclitaxel spinal nerves ligation MDA-19 MDA19 CBs peripheral central MDAs central cannabinoids cbs synthetic cannabinoids Epidermal Growth Factor Receptor Protein-Tyrosine Kinase Receptors, Epidermal Growth Factor-Urogastrone Receptor Transforming Growth Factor alpha Transforming Growth Factor alpha Receptor Epidermal Growth Factor Receptor Kinase Receptor Epidermal Growth Factor Receptor erbB 1 Proto Oncogene Protein Receptor Urogastrone Urogastrone Receptor Receptor TGF alpha TGF-alpha Receptor c-erbB-1 Protein Proto-Oncogene Receptor EGF EGF Receptor analytical references standards
Product Overview:
MDA 19 is a selective agonist of the human peripheral cannabinoid (CB2) receptor, with an EC50 value for activation (63.4 nM) that is 14-fold lower than that for central cannabinoid (CB1) activation (EC50 = 867 nM).{18383} Surprisingly, it acts as an inverse agonist at the rat CB2 receptor in cell-based functional assays.{18533} MDA 19 attenuates tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and in CB2+/+ mice but not in CB2-/- mice, indicating that CB2 receptors mediated the effects of MDA 19.{18383,18533} These effects of MDA 19 are blocked by the selective CB2 antagonist AM630.{18383}
Size 1 mg
Shipping dry ice
CAS Number 1048973-47-2
Molecular Formula C21H23N3O2
Molecular Weight 349,4
Formulation A crystalline solid
Purity ≥95%
Custom Code 2916.31
UNSPSC code 12352100

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : MDA 19 There are 10 products.